Hologic price target lowered to $83 from $95 at Needham

Needham analyst Mike Matson lowered the firm’s price target on Hologic to $83 from $95 and keeps a Buy rating on the shares. The firm is updating its valuation to reflect the company’s commentary and rising interest rates while also citing peer multiple contraction in its price target cut.